Pfizer stocks surge after secret Trump-Pfizer deal that sparkd FOIA demands and public outcry
Pfizer may already have been planning to spend the $70 billion that it committed to allocate to US manufacturing, BMO Capital Markets analyst Evan David Seigerman told the WSJ.
